Amgen, Inc. (NASDAQ:AMGN) Receives $217.56 Average Price Target from Analysts

Share on StockTwits

Amgen, Inc. (NASDAQ:AMGN) has earned an average rating of “Hold” from the twenty-one ratings firms that are currently covering the stock, Marketbeat Ratings reports. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $218.13.

Several brokerages have issued reports on AMGN. Mizuho downgraded shares of Amgen from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $208.00 to $212.00 in a research report on Monday, August 19th. They noted that the move was a valuation call. Morgan Stanley reduced their target price on shares of Amgen from $211.00 to $207.00 and set an “overweight” rating for the company in a research note on Monday, July 15th. Piper Jaffray Companies lifted their target price on shares of Amgen from $210.00 to $218.00 and gave the company an “overweight” rating in a report on Monday, August 26th. BMO Capital Markets boosted their price target on shares of Amgen from $230.00 to $240.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 27th. Finally, JPMorgan Chase & Co. set a $198.00 price target on shares of Amgen and gave the stock a “hold” rating in a report on Friday.

Shares of AMGN stock traded down $5.47 during midday trading on Thursday, hitting $196.87. The company had a trading volume of 4,377,198 shares, compared to its average volume of 3,052,051. The stock has a market cap of $124.58 billion, a price-to-earnings ratio of 13.67, a PEG ratio of 2.44 and a beta of 1.11. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. The company’s 50 day simple moving average is $195.79 and its 200 day simple moving average is $185.11. Amgen has a 52-week low of $166.30 and a 52-week high of $211.90.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The business had revenue of $5.87 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the prior year, the business earned $3.83 earnings per share. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. Analysts anticipate that Amgen will post 14.25 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 6th. Stockholders of record on Thursday, August 15th were paid a dividend of $1.45 per share. The ex-dividend date was Wednesday, August 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.95%. Amgen’s dividend payout ratio (DPR) is presently 40.28%.

In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total transaction of $375,160.00. Following the sale, the director now owns 16,336 shares of the company’s stock, valued at $3,064,306.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total transaction of $77,792.00. Following the transaction, the director now owns 16,336 shares in the company, valued at $2,990,141.44. The disclosure for this sale can be found here. Insiders sold a total of 17,851 shares of company stock valued at $3,659,900 in the last quarter. Insiders own 0.25% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Advisors Preferred LLC purchased a new position in shares of Amgen in the second quarter valued at $30,000. Arbor Wealth Management LLC grew its stake in Amgen by 154.5% in the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 102 shares during the last quarter. C J Advisory Inc purchased a new position in Amgen during the 1st quarter valued at about $40,000. Ashburton Jersey Ltd purchased a new position in Amgen during the 2nd quarter valued at about $42,000. Finally, Sound Income Strategies LLC increased its holdings in Amgen by 402.1% during the 2nd quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock valued at $43,000 after acquiring an additional 189 shares in the last quarter. Institutional investors own 76.28% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: Swap

Analyst Recommendations for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Sterling Capital Management LLC Grows Stock Holdings in Vanguard Real Estate ETF
Sterling Capital Management LLC Grows Stock Holdings in Vanguard Real Estate ETF
Prospera Financial Services Inc Makes New $210,000 Investment in iShares MSCI Eurozone ETF
Prospera Financial Services Inc Makes New $210,000 Investment in iShares MSCI Eurozone ETF
Sterling Capital Management LLC Grows Stock Holdings in Cardtronics PLC
Sterling Capital Management LLC Grows Stock Holdings in Cardtronics PLC
Brokerages Set ONE Gas Inc  Price Target at $82.50
Brokerages Set ONE Gas Inc Price Target at $82.50
Summit Street Capital Management LLC Has $3.73 Million Stock Position in KLA-Tencor Corp
Summit Street Capital Management LLC Has $3.73 Million Stock Position in KLA-Tencor Corp
Citizens Community Bancorp Inc.  Given Consensus Recommendation of “Buy” by Analysts
Citizens Community Bancorp Inc. Given Consensus Recommendation of “Buy” by Analysts


 
© 2006-2019 Zolmax.